Daniela Ferreira

Person icon

Professor of Respiratory Infection and Vaccinology

University of Oxford, Liverpool School of Tropical Medicine (LSTM), United Kingdom (UK)

Email: daniela.ferreira@paediatrics.ox.ac.uk

 

 

 

 

VALIDATE Role:

Network Investigator

 

Research Keywords:

Human Challenge Models, Controlled Human Infection, Clinical Trials, Immunology

 

Biography:

Professor Daniela Ferreira is an internationally recognised expert in respiratory mucosal immunity and Controlled Human Infection Models (CHIMs). She is Professor of Respiratory Infection and Vaccinology at the University of Oxford and Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine (LSTM).

Daniela leads a translational research team, collaborating with partners worldwide and securing significant funding from major organisations and industry. Her team have delivered ambitious clinical studies, including human challenge trials, and played a key role in COVID-19 vaccine research and national/international responses to the pandemic. Daniela’s work focuses on understanding immune responses to respiratory infections, such as pneumococcus, SARS-CoV-2, RSV, and influenza, and how factors like co-infections and host susceptibility influence outcomes. She holds leadership roles across major research consortia, including HIC-VAC and iiCON.

 

Related Websites:

University of Oxford

 

Key Publications:

  • Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al.; COVID-19 Genomics UK consortium; Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARSCoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351–1362. doi: 10.1016/S0140-6736(21)00628-0.
  • Doherty K, Dula D, Chirwa A, Nsomba E, Nkhoma VS, Toto N, et al. Ferreira DM. Experimental pneumococcal carriage in people living with HIV in Malawi: the first controlled human infection model in a key at-risk population. Wellcome Open Res. 2024;9:2. Position: Last author.
  • Mitsi E, Nikolaou E, Goncalves A, Blizard A, Hill H, Farrar M, et al. Ferreira DM. RSV and Rhinovirus increase pneumococcal carriage acquisition and density whereas nasal inflammation is associated with bacterial shedding. Cell Host and Microbe. July 2024. (In press).
  • Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, et al. Controlled Human Infection and Re-Challenge with Streptococcus pneumoniae Reveals the Protective Efficacy of Carriage in Healthy Adults. Am J Respir Crit Care Med. 2013.
  • Hill H, Mitsi E, Nikolaou E, Blizard A, Pojar S, Howard A, et al. Ferreira DM. A Randomized Controlled Clinical Trial of Nasal Immunization with Live Virulence Attenuated Streptococcus pneumoniae Strains Using Human Infection Challenge. Am J Respir Crit Care Med. 2023;208(8):868–878.
  • Mitsi E, Carniel B, Reiné J, Rylance J, Zaidi S, Soares-Schanoski A, et al. Ferreira DM. Nasal Pneumococcal Density is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens. Am J Respir Crit Care Med. 2019.
  • Pennington SH, Pojar S, Mitsi E, Gritzfeld JF, Nikolaou E, Solórzano C, et al. Ferreira DM. Polysaccharide-specific Memory B-cells Predict Protection Against Experimental Human Pneumococcal Carriage. Am J Respir Crit Care Med.2016;194(12):1523–1531.
  • Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordmüller B, Yazdanbakhsh M. Experimental infection of human volunteers. Lancet Infect Dis. 2018.
  • Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, Ferreira DM, Gordon SB. Experimental human pneumococcal carriage. J Vis Exp. 2013.
  • Ferreira DM, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends in Microbiology. 2011;19(9):464–70.